Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2019

30.01.2019 | Short Communication

Highlights of Abstracts on Plasma Cell Dyscrasia in the Annual Conference ISHBT (Kochi)

verfasst von: Tathagat Chatterjee, Ankur Ahuja

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Since last few years plasma cell dyscrasias have been in the hit list of research especially pertaining to its therapy and pathophysiology. India has taken a great leap as far as research in plasma cell dyscrasias is concerned. The year started with myeloma conference in New Delhi conducted by Army Hospital (R&R) and ended at Haematocon Kochi organised by team from CMC Vellore (Haematocon 2018). Haematocon 2018 provided an exceptional platform for the research on various aspects of plasma cell dyscrasias both from the country and abroad. A total of 23 abstracts were presented pertaining to plasma cell disorders; 13 original research papers, 08 case reports and 02 case series. There were a wide spectrum of papers which ranged from the discussion about morphological aspects, mimickers, clinical spectrum, life style in the setting of the disease, diagnostic modalities to management aspects and finally to progress and survival of these patients. Through this review we will summarize and analyze the key findings of the original research abstracts on diagnosis, risk stratification, clinical profile and treatment aspects of plasma cell disorders presented at the Haematocon 2018.
Literatur
1.
Zurück zum Zitat Shruthi V, Manipadam MT, Geevar T (2018) Looks can be deceptive-anaplastic myeloma mimicking myelodysplastic syndrome (Haematocon 2018-257). Indian J Hematol Blood Transfus 34(issue 1 supplement):365 Shruthi V, Manipadam MT, Geevar T (2018) Looks can be deceptive-anaplastic myeloma mimicking myelodysplastic syndrome (Haematocon 2018-257). Indian J Hematol Blood Transfus 34(issue 1 supplement):365
2.
Zurück zum Zitat Agarwal A, Singh A, Tanweer N (2018) Plasma cell leukemia with plasmablastic morphology mimicking acute myeloid leukaemia—a rare case report (Haematocon 2018-420). Indian J Hematol Blood Transfus 34(issue 1 supplement):262 Agarwal A, Singh A, Tanweer N (2018) Plasma cell leukemia with plasmablastic morphology mimicking acute myeloid leukaemia—a rare case report (Haematocon 2018-420). Indian J Hematol Blood Transfus 34(issue 1 supplement):262
3.
Zurück zum Zitat Monica S, Khan EM, Basu A (2018) A case of multiple myeloma with plasmablastic morphology—a rare variant (Haematocon 2018-228). Indian J Hematol Blood Transfus 34(issue 1 supplement):362 Monica S, Khan EM, Basu A (2018) A case of multiple myeloma with plasmablastic morphology—a rare variant (Haematocon 2018-228). Indian J Hematol Blood Transfus 34(issue 1 supplement):362
4.
Zurück zum Zitat Venkatesan S, Sharma S (2018) Unusual morphological variants of plasma cell neoplasms (Haematocon 2018-294). Indian J Hematol Blood Transfus (issue 1 supplement):366 Venkatesan S, Sharma S (2018) Unusual morphological variants of plasma cell neoplasms (Haematocon 2018-294). Indian J Hematol Blood Transfus (issue 1 supplement):366
5.
Zurück zum Zitat Banerjee SS, Verma S, Shanks JH (2004) Morphological variants of plasma cell tumours. Histopathology 44:2–8CrossRefPubMed Banerjee SS, Verma S, Shanks JH (2004) Morphological variants of plasma cell tumours. Histopathology 44:2–8CrossRefPubMed
6.
Zurück zum Zitat Manasa Ravath CJ, Kulkarni N, Vinod R (2017) Mott cells—at a glance. Int J Contemp Med Res 4(1):43–44 Manasa Ravath CJ, Kulkarni N, Vinod R (2017) Mott cells—at a glance. Int J Contemp Med Res 4(1):43–44
7.
Zurück zum Zitat Kumar K, Ningombam A, Irshad M, Parshuram PP (2018) Mott cells in peripheral blood smear of dengue fever (Haematocon 2018-596). Indian J Hematol Blood Transfus (issue 1 supplement):226 Kumar K, Ningombam A, Irshad M, Parshuram PP (2018) Mott cells in peripheral blood smear of dengue fever (Haematocon 2018-596). Indian J Hematol Blood Transfus (issue 1 supplement):226
8.
Zurück zum Zitat Dhiman P, Goel S, Samal P, Sood N, Sachdev R, Yadav SP, Vaid AK (2016) FISH analysis in multiple myeloma—a retrospective study from India. Blood 128(22):5646 Dhiman P, Goel S, Samal P, Sood N, Sachdev R, Yadav SP, Vaid AK (2016) FISH analysis in multiple myeloma—a retrospective study from India. Blood 128(22):5646
9.
Zurück zum Zitat Janet NB, Devasia AJ, Palle A, Maniapadam MT et al (2018) Multiple myeloma risk stratification by FISH analysis—a single centre experience. (Haematocon 2018-518). Indian J Hematol Blood Transfus 34(issue 1 supplement):374 Janet NB, Devasia AJ, Palle A, Maniapadam MT et al (2018) Multiple myeloma risk stratification by FISH analysis—a single centre experience. (Haematocon 2018-518). Indian J Hematol Blood Transfus 34(issue 1 supplement):374
10.
Zurück zum Zitat Szabo AG, Gang AO, Poulsen TS, Klausen TW, Nørgaard PH (2012) T(11;14), cyclin D1, CD20 and CD56 in multiple myeloma: a retrospective study of pathologic and clinical associations. Blood 120:4983 Szabo AG, Gang AO, Poulsen TS, Klausen TW, Nørgaard PH (2012) T(11;14), cyclin D1, CD20 and CD56 in multiple myeloma: a retrospective study of pathologic and clinical associations. Blood 120:4983
11.
Zurück zum Zitat Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ et al (2003) CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 102(3):10701CrossRef Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ et al (2003) CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 102(3):10701CrossRef
12.
Zurück zum Zitat Khan SHA, Mahesh K, Varghese RG (2018) Expression of Cd 20 and cyclin D1 in bone marrow biopsy of patients with multiple myeloma and its correlation with morphological features. (Haematocon 2018-180). Indian J Hematol Blood Transfus 34(issue 1 supplement):361 Khan SHA, Mahesh K, Varghese RG (2018) Expression of Cd 20 and cyclin D1 in bone marrow biopsy of patients with multiple myeloma and its correlation with morphological features. (Haematocon 2018-180). Indian J Hematol Blood Transfus 34(issue 1 supplement):361
13.
Zurück zum Zitat Hallgrimsdottir T, Porwit A, Björkholm M, Rossmann E, Steingrimsdottir H, Lund SH, Kristinsson SY (1946) Bone marrow fibrosis in patients with multiple myeloma: a new prognostic factor for survival? Blood 2013:122 Hallgrimsdottir T, Porwit A, Björkholm M, Rossmann E, Steingrimsdottir H, Lund SH, Kristinsson SY (1946) Bone marrow fibrosis in patients with multiple myeloma: a new prognostic factor for survival? Blood 2013:122
14.
Zurück zum Zitat Murthy P, Mahajan S, Singh T (2018) Bone marrow fibrosis in multiple myeloma. (Haematocon 2018-367). Indian J Hematol Blood Transfus 34(supplement):370 Murthy P, Mahajan S, Singh T (2018) Bone marrow fibrosis in multiple myeloma. (Haematocon 2018-367). Indian J Hematol Blood Transfus 34(supplement):370
15.
Zurück zum Zitat Coppola A, Tufano A, Di Capua M, Franchini M (2011) Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 37(8):929–945CrossRefPubMed Coppola A, Tufano A, Di Capua M, Franchini M (2011) Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 37(8):929–945CrossRefPubMed
16.
Zurück zum Zitat Purohit A, Bohra GK, Bohra HK, Ahari K (2018) Multiple myeloma presenting as bleeding diathesis—an atypical presentation. (Haematocon 2018-321). Indian J Hematol Blood Transfus 34(supplement):367 Purohit A, Bohra GK, Bohra HK, Ahari K (2018) Multiple myeloma presenting as bleeding diathesis—an atypical presentation. (Haematocon 2018-321). Indian J Hematol Blood Transfus 34(supplement):367
17.
Zurück zum Zitat Heinz Ludwig P et al (2008) Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 111:4039CrossRefPubMedPubMedCentral Heinz Ludwig P et al (2008) Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 111:4039CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Rumi MSIS, Chowdhury S, Jahan D, Muquit T, Saleh A (2018) A-29-year young male patient with multiple myeloma. (Haematocon 2018-392). Indian J Hematol Blood Transfus 34(supplement):371 Rumi MSIS, Chowdhury S, Jahan D, Muquit T, Saleh A (2018) A-29-year young male patient with multiple myeloma. (Haematocon 2018-392). Indian J Hematol Blood Transfus 34(supplement):371
19.
Zurück zum Zitat Dimopoulos MA, Sonneveld P, Leung N et al (2016) International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34(13):1544–1557CrossRefPubMed Dimopoulos MA, Sonneveld P, Leung N et al (2016) International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34(13):1544–1557CrossRefPubMed
20.
Zurück zum Zitat Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C, On Behalf of the ESMO Guidelines Committee (2017) Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv52–iv61CrossRefPubMed Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C, On Behalf of the ESMO Guidelines Committee (2017) Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv52–iv61CrossRefPubMed
21.
Zurück zum Zitat Terpos E, Kleber M, Engelhardt M et al (2015) European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica 100:1254–1266CrossRefPubMedPubMedCentral Terpos E, Kleber M, Engelhardt M et al (2015) European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica 100:1254–1266CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Dimopoulos MA, Terpos E, Chanan-Khan A et al (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf the International Myeloma Working Group. J Clin Oncol 28:4976–4984CrossRefPubMed Dimopoulos MA, Terpos E, Chanan-Khan A et al (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf the International Myeloma Working Group. J Clin Oncol 28:4976–4984CrossRefPubMed
23.
Zurück zum Zitat Nath UK, Chetia R. Renal salvage with bortezomib/cyclophosphamide/dexamethasone therapy in newly diagnosed multiple myeloma patients with renal insufficiency: a single-center study. (Haematocon 2018-396). Indian J Hematol Blood Transfus 34(supplement):60 Nath UK, Chetia R. Renal salvage with bortezomib/cyclophosphamide/dexamethasone therapy in newly diagnosed multiple myeloma patients with renal insufficiency: a single-center study. (Haematocon 2018-396). Indian J Hematol Blood Transfus 34(supplement):60
25.
Zurück zum Zitat Cavo M, Pantani L, Pezzi A, Petrucci MT, Patriarca F, Di Raimondo F, Marzocchi G, Galli M, Montefusco V, Zamagni E, Gamberi B, Tacchetti P, Brioli A, Palumbo A, Sonneveld P (2015) Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Leukemia 29:2429–2431CrossRefPubMed Cavo M, Pantani L, Pezzi A, Petrucci MT, Patriarca F, Di Raimondo F, Marzocchi G, Galli M, Montefusco V, Zamagni E, Gamberi B, Tacchetti P, Brioli A, Palumbo A, Sonneveld P (2015) Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Leukemia 29:2429–2431CrossRefPubMed
26.
Zurück zum Zitat Kumar NM, Kalita PP, Bhattacharya J, Dutta S, Talukdar A, Barman R (2018) Study on prognostic factors and short term outcome of treatment of multiple myeloma patients at a tertiary care hospital. (Haematocon 2018-363). Indian J Hematol Blood Transfus 34(supplement):369 Kumar NM, Kalita PP, Bhattacharya J, Dutta S, Talukdar A, Barman R (2018) Study on prognostic factors and short term outcome of treatment of multiple myeloma patients at a tertiary care hospital. (Haematocon 2018-363). Indian J Hematol Blood Transfus 34(supplement):369
27.
Zurück zum Zitat Jitani AK, Dolai TK, Mandal PK, Baul SN et al (2018) Bortezomib-thalidomide-dexamethasone (Vtd) in newly diagnosed multiple myeloma: a real world experience. (Haematocon 2018-242). Indian J Hematol Blood Transfus 34(supplement):364 Jitani AK, Dolai TK, Mandal PK, Baul SN et al (2018) Bortezomib-thalidomide-dexamethasone (Vtd) in newly diagnosed multiple myeloma: a real world experience. (Haematocon 2018-242). Indian J Hematol Blood Transfus 34(supplement):364
28.
Zurück zum Zitat Uysal A, Akad Soyer N, Özkan M, Şahin F, Vural F, Töbü M, Tombuloğlu M, Saydam G (2018) Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience. Turk J Med Sci 48(1):80–83CrossRefPubMed Uysal A, Akad Soyer N, Özkan M, Şahin F, Vural F, Töbü M, Tombuloğlu M, Saydam G (2018) Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience. Turk J Med Sci 48(1):80–83CrossRefPubMed
29.
Zurück zum Zitat Demopoulos MA, Goldschmidt H, Niesvizky R et al (2017) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18:1327–1337CrossRef Demopoulos MA, Goldschmidt H, Niesvizky R et al (2017) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18:1327–1337CrossRef
30.
Zurück zum Zitat Sandal R, Jandial A, Mishra K, Lad D et al (2018) Real world experience of generic carfilzomib for relapsed refractory multiple myeloma (Rrmm). (Haematocon 2018-515). Indian J Hematol Blood Transfus 34(supplement):372 Sandal R, Jandial A, Mishra K, Lad D et al (2018) Real world experience of generic carfilzomib for relapsed refractory multiple myeloma (Rrmm). (Haematocon 2018-515). Indian J Hematol Blood Transfus 34(supplement):372
31.
Zurück zum Zitat Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L et al (2018) From transplant to novel cellular therapies in multiple myeloma: European myeloma network guidelines and future perspectives. Haematologica 103(2):197–211CrossRefPubMedPubMedCentral Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L et al (2018) From transplant to novel cellular therapies in multiple myeloma: European myeloma network guidelines and future perspectives. Haematologica 103(2):197–211CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Uday Y, Yadav S, Das SR, Kapoor R et al (2018) Multiple myeloma- real world experience of transplantation in multiple myeloma from a tertiary care centre in North India. (Haematocon 2018-573). Indian J Hematol Blood Transfus 34(supplement):61 Uday Y, Yadav S, Das SR, Kapoor R et al (2018) Multiple myeloma- real world experience of transplantation in multiple myeloma from a tertiary care centre in North India. (Haematocon 2018-573). Indian J Hematol Blood Transfus 34(supplement):61
33.
Zurück zum Zitat Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C et al (2018) Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) study. A report by the EBMT chronic malignancies working party. Haematologica 103(3):514–521CrossRefPubMedPubMedCentral Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C et al (2018) Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) study. A report by the EBMT chronic malignancies working party. Haematologica 103(3):514–521CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Kardduss-Urueta A, Gale RP, Gutierrez-Aguirre CH, Herrera-Rojas MA, Murrieta-Álvarez I, PerezFontalvo R, Ruiz-Delgado GJ, Ruiz-Rojas G, Jaimovich G, Feldman L, Labastida-Mercado N, Endara A, Castro M, Galindo-Becerra S, Cardona-Molina MA, Gomez-Almaguer D, Ruiz-Argüelles GJ (2018) Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas. Bone Marrow Transplant 53:457–460CrossRefPubMed Kardduss-Urueta A, Gale RP, Gutierrez-Aguirre CH, Herrera-Rojas MA, Murrieta-Álvarez I, PerezFontalvo R, Ruiz-Delgado GJ, Ruiz-Rojas G, Jaimovich G, Feldman L, Labastida-Mercado N, Endara A, Castro M, Galindo-Becerra S, Cardona-Molina MA, Gomez-Almaguer D, Ruiz-Argüelles GJ (2018) Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas. Bone Marrow Transplant 53:457–460CrossRefPubMed
35.
Zurück zum Zitat Kulkarni U, Devasia AJ, Korula A, Fouzia NA et al (2018) Use of non-cryopreserved peripheral blood stem cells is associated with adequate engraftment in patients with multiple myeloma undergoing an autologous transplant. (Haematocon 2018-522). Indian J Hematol Blood Transfus 34(supplement):63 Kulkarni U, Devasia AJ, Korula A, Fouzia NA et al (2018) Use of non-cryopreserved peripheral blood stem cells is associated with adequate engraftment in patients with multiple myeloma undergoing an autologous transplant. (Haematocon 2018-522). Indian J Hematol Blood Transfus 34(supplement):63
36.
Zurück zum Zitat Raghavan V, Nair CK, Avaronnan M, Shenoy PK et al (2018) Unmet needs in multiple myeloma patients: experience from a tertiary cancer centre in South India. (Haematocon 2018-532). Indian J Hematol Blood Transfus 34(supplement):375 Raghavan V, Nair CK, Avaronnan M, Shenoy PK et al (2018) Unmet needs in multiple myeloma patients: experience from a tertiary cancer centre in South India. (Haematocon 2018-532). Indian J Hematol Blood Transfus 34(supplement):375
37.
Zurück zum Zitat Avaronnan M, Raghavan V, Shenoy PK, Sanjeev Kumar PB et al (2018) Health related quality of life in patients with multiple myeloma on novel agents: experience from a tertiary cancer centre in south India. (Haematocon 2018-568). Indian J Hematol Blood Transfus 34(supplement):376 Avaronnan M, Raghavan V, Shenoy PK, Sanjeev Kumar PB et al (2018) Health related quality of life in patients with multiple myeloma on novel agents: experience from a tertiary cancer centre in south India. (Haematocon 2018-568). Indian J Hematol Blood Transfus 34(supplement):376
Metadaten
Titel
Highlights of Abstracts on Plasma Cell Dyscrasia in the Annual Conference ISHBT (Kochi)
verfasst von
Tathagat Chatterjee
Ankur Ahuja
Publikationsdatum
30.01.2019
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2019
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01075-z

Weitere Artikel der Ausgabe 1/2019

Indian Journal of Hematology and Blood Transfusion 1/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.